NCT07250763Active, not recruitingPhase 4
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
Optimization of Intravenous Unfractionated Heparin Starting Infusion Rate for Adult Patients With Deep Vein Thrombosis/Pulmonary Embolism or Cardiac Indications
Source: ClinicalTrials.gov · Last updated 26 Nov 2025
Brief summary (registry, in English)
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 145 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 20 Sept 2023
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- Inova Health Care Services
- Diseases
- Atrial fibrillation
- NCT number
- NCT07250763
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 145
- From 20 Sept 2023 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent use of direct-acting oral anticoagulants or low molecular weight heparins
Other
- Use of extracorporeal membrane oxygenation or ventricular assist devices such as Impella pumps
- Diagnosis of thrombophilia/hypercoagulable state
- Baseline anti-Xa \> 0.7
- Pregnancy
Who the study is looking for
- Age \> 18 years-old
- Diagnosis by the attending physician with one of the following conditions for which anticoagulation with heparin in an Food \& Drug Administration approved indication and considered the standard of care:
- Moderate-intensity anti-Xa protocol: new-onset deep vein thrombosis or pulmonary embolism, or mechanical heart valve
- Low-intensity anti-Xa protocol: atrial fibrillation, acute cardiac syndrome, embolic stroke
- Heparin infusion either has not started or has been initiated in the last 120 minutes
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Inova Alexandria Hospital Coordinator of this site? Confirm its status | Alexandria | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.